JP2016530504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530504A5 JP2016530504A5 JP2016525390A JP2016525390A JP2016530504A5 JP 2016530504 A5 JP2016530504 A5 JP 2016530504A5 JP 2016525390 A JP2016525390 A JP 2016525390A JP 2016525390 A JP2016525390 A JP 2016525390A JP 2016530504 A5 JP2016530504 A5 JP 2016530504A5
- Authority
- JP
- Japan
- Prior art keywords
- metabolites
- acid
- autistic
- increased
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002207 metabolite Substances 0.000 claims 159
- 150000003384 small molecules Chemical class 0.000 claims 24
- 238000000034 method Methods 0.000 claims 23
- 206010003805 Autism Diseases 0.000 claims 20
- 208000020706 Autistic disease Diseases 0.000 claims 20
- 238000004811 liquid chromatography Methods 0.000 claims 16
- 238000000132 electrospray ionisation Methods 0.000 claims 15
- 150000002500 ions Chemical class 0.000 claims 14
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 10
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 claims 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 10
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims 10
- 238000002705 metabolomic analysis Methods 0.000 claims 10
- 230000001431 metabolomic effect Effects 0.000 claims 10
- 239000004474 valine Substances 0.000 claims 10
- JJMDCOVWQOJGCB-UHFFFAOYSA-N delta-aminovaleric acid Natural products [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims 9
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 8
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 claims 8
- ZDGJAHTZVHVLOT-YUMQZZPRSA-N L-saccharopine Chemical compound OC(=O)[C@@H](N)CCCCN[C@H](C(O)=O)CCC(O)=O ZDGJAHTZVHVLOT-YUMQZZPRSA-N 0.000 claims 8
- 229960003067 cystine Drugs 0.000 claims 8
- 230000003247 decreasing effect Effects 0.000 claims 8
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 claims 8
- 230000003993 interaction Effects 0.000 claims 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 6
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 claims 6
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 229960000310 isoleucine Drugs 0.000 claims 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 6
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 claims 4
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 claims 4
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 4
- -1 5- aminovaleric acid lactam Chemical class 0.000 claims 4
- ZMITXKRGXGRMKS-UHFFFAOYSA-N Androsteronsulfat-pyridiniumsalz Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 ZMITXKRGXGRMKS-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- ZDGJAHTZVHVLOT-UHFFFAOYSA-N L-Saccharopine Natural products OC(=O)C(N)CCCCNC(C(O)=O)CCC(O)=O ZDGJAHTZVHVLOT-UHFFFAOYSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 4
- ZMITXKRGXGRMKS-HLUDHZFRSA-N androsterone sulfate Chemical compound C1[C@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 ZMITXKRGXGRMKS-HLUDHZFRSA-N 0.000 claims 4
- 229940009098 aspartate Drugs 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 229930195712 glutamate Natural products 0.000 claims 4
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 4
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims 4
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 4
- LFLUCDOSQPJJBE-UHFFFAOYSA-N 3-phosphonooxypyruvic acid Chemical compound OC(=O)C(=O)COP(O)(O)=O LFLUCDOSQPJJBE-UHFFFAOYSA-N 0.000 claims 3
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 claims 2
- OTXFQGQBMBVGOO-XSLNCIIRSA-N (3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-heptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCCC)[C@@]1(C)CC2 OTXFQGQBMBVGOO-XSLNCIIRSA-N 0.000 claims 2
- SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 claims 2
- WMCQWXZMVIETAO-UHFFFAOYSA-N 2-(2-carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic acid Chemical compound CCCC=1OC(CCC(O)=O)=C(C(O)=O)C=1C WMCQWXZMVIETAO-UHFFFAOYSA-N 0.000 claims 2
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 claims 2
- AXPAUZGVNGEWJD-UHFFFAOYSA-N 2-methylhexadecanoic acid Chemical compound CCCCCCCCCCCCCCC(C)C(O)=O AXPAUZGVNGEWJD-UHFFFAOYSA-N 0.000 claims 2
- NOVZJYYJYIFXJC-MZMPXXGTSA-N 2-oleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)O[C@H](CO)COP(O)(=O)OCCN NOVZJYYJYIFXJC-MZMPXXGTSA-N 0.000 claims 2
- JVGVDSSUAVXRDY-UHFFFAOYSA-N 3-(4-hydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-N 0.000 claims 2
- CZWARROQQFCFJB-BYPYZUCNSA-N 5-hydroxy norvaline Chemical compound OC(=O)[C@@H](N)CCCO CZWARROQQFCFJB-BYPYZUCNSA-N 0.000 claims 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 108010007979 Glycocholic Acid Proteins 0.000 claims 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- JRLGPAXAGHMNOL-LURJTMIESA-N N(2)-acetyl-L-ornithine Chemical compound CC(=O)N[C@H](C([O-])=O)CCC[NH3+] JRLGPAXAGHMNOL-LURJTMIESA-N 0.000 claims 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims 2
- 229960005164 acesulfame Drugs 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 210000004381 amniotic fluid Anatomy 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- 229960005261 aspartic acid Drugs 0.000 claims 2
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 2
- 229960001231 choline Drugs 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 2
- 229940099347 glycocholic acid Drugs 0.000 claims 2
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- XEVRBOQZSXWGQO-PAUXXPOVSA-N lysophosphatidylethanolamine (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OC[C@@H](O)COP(O)(=O)OCCN XEVRBOQZSXWGQO-PAUXXPOVSA-N 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 229960002429 proline Drugs 0.000 claims 2
- 229960001153 serine Drugs 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 2
- 229960004799 tryptophan Drugs 0.000 claims 2
- 229940116269 uric acid Drugs 0.000 claims 2
- 229960004295 valine Drugs 0.000 claims 2
- LFLUCDOSQPJJBE-UHFFFAOYSA-K 3-phosphonatooxypyruvate(3-) Chemical compound [O-]C(=O)C(=O)COP([O-])([O-])=O LFLUCDOSQPJJBE-UHFFFAOYSA-K 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 238000013459 approach Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844128P | 2013-07-09 | 2013-07-09 | |
| US61/844,128 | 2013-07-09 | ||
| US201461996835P | 2014-05-14 | 2014-05-14 | |
| US61/996,835 | 2014-05-14 | ||
| PCT/US2014/045397 WO2015006160A2 (en) | 2013-07-09 | 2014-07-03 | Biomarkers of autism spectrum disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530504A JP2016530504A (ja) | 2016-09-29 |
| JP2016530504A5 true JP2016530504A5 (enExample) | 2017-07-27 |
| JP6763770B2 JP6763770B2 (ja) | 2020-09-30 |
Family
ID=52280698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525390A Expired - Fee Related JP6763770B2 (ja) | 2013-07-09 | 2014-07-03 | 自閉症スペクトラム障害のバイオマーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10060932B2 (enExample) |
| EP (1) | EP3019624B1 (enExample) |
| JP (1) | JP6763770B2 (enExample) |
| CA (1) | CA2917483A1 (enExample) |
| MX (1) | MX2016000293A (enExample) |
| WO (1) | WO2015006160A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| WO2017197252A1 (en) * | 2016-05-13 | 2017-11-16 | Stemina Biomarker Discovery, Inc. | Autism subsets |
| KR102328323B1 (ko) | 2017-03-31 | 2021-11-19 | 엑시얼 테라퓨틱스, 인크. | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 |
| US12080432B1 (en) | 2017-06-01 | 2024-09-03 | The Regents Of The University Of Colorado | Plasma metabolome as a predictor of biological aging |
| EP3746796A4 (en) * | 2018-01-29 | 2021-12-22 | Stemina Biomarker Discovery, Inc. | DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISORDERS BASED ON METABOTYPES CONTAINING AN AMINE |
| CN109813912B (zh) * | 2019-01-04 | 2021-12-28 | 深圳大学 | 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用 |
| CA3136303A1 (en) | 2019-04-05 | 2020-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic for childhood risk of autism spectrum disorder |
| EP3948277A4 (en) | 2019-04-05 | 2023-05-24 | Arizona Board of Regents on behalf of Arizona State University | METABOLITES AS DIAGNOSTICS OF AUTISTIC SPECTRUM DISEASE IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS |
| CN113906296B (zh) * | 2019-04-23 | 2024-11-15 | 中国医学科学院北京协和医院 | 基于机器学习的使用代谢物作为标记物的孤独症谱系障碍诊断方法和装置 |
| EP3963323A4 (en) * | 2019-05-02 | 2023-05-31 | Stemina Biomarker Discovery, Inc. | DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISEASES RELATED TO ALTERED METABOLIC PATHWAYS |
| EP3980764A4 (en) * | 2019-06-06 | 2023-07-05 | Icahn School of Medicine at Mount Sinai | SYSTEMS AND METHODS FOR DIAGNOSIS OF BIOLOGICAL DISEASES RELATED TO PERIODIC VARIATIONS OF METAL METABOLISM |
| US20220146527A1 (en) * | 2019-09-17 | 2022-05-12 | Chang Gung University | Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms |
| WO2021072351A1 (en) * | 2019-10-11 | 2021-04-15 | Stemina Biomarker Discovery, Inc. | Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolite concentrations |
| US20240369538A1 (en) * | 2019-10-16 | 2024-11-07 | Rene Anand | Live Virus Vaccine Injury Risk |
| CN116547520A (zh) * | 2020-09-21 | 2023-08-04 | 分子优公司 | 孤独症谱系障碍的诊断与治疗方法 |
| CA3193117A1 (en) * | 2020-09-21 | 2022-03-24 | Mohammad Ashraful Anwar | Method of diagnosis and treatment of autism spectrum disorder |
| EP4222501A1 (en) * | 2020-10-24 | 2023-08-09 | Universitätsspital Basel | Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma |
| EP4012414A1 (en) * | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
| CN113125588B (zh) * | 2021-03-17 | 2022-01-14 | 广东省农业科学院农业质量标准与监测技术研究所 | 一种代谢组学分析技术判别鸭屎香单丛茶时空分类的应用 |
| KR102530345B1 (ko) * | 2021-08-04 | 2023-05-10 | 단국대학교 천안캠퍼스 산학협력단 | 대사체 프로파일링을 이용한 자폐 스펙트럼 장애의 진단용 조성물 및 이를 포함하는 진단키트 |
| JP2024134052A (ja) * | 2023-03-20 | 2024-10-03 | 株式会社島津製作所 | データ処理方法、データ処理装置およびプログラム |
| US20260017793A1 (en) * | 2024-07-12 | 2026-01-15 | University Of Louisville Research Foundation, Inc. | Computer-aided system and method for determination of autism spectrum disorder severity by assessment module |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686311A (en) * | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
| US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
| WO2001079837A1 (en) | 2000-04-12 | 2001-10-25 | Repligen Corporation | Methylxanthines in the diagnosis and treatment of autistic disorder |
| WO2001078652A2 (en) | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US20080154332A1 (en) * | 2001-12-24 | 2008-06-26 | The Cleveland Clinic Foundation | Modulation of the Brain to Affect Psychiatric Disorders and Functions |
| US8131473B1 (en) | 2004-05-20 | 2012-03-06 | Metabolon, Inc. | Data analysis methods for locating entities of interest within large, multivariable datasets |
| GB0504096D0 (en) | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| WO2006121952A2 (en) | 2005-05-05 | 2006-11-16 | The Regents Of The University Of California | Diagnostic biomarkers for neurodevelopmental disorders |
| US20070023677A1 (en) * | 2005-06-29 | 2007-02-01 | Perkins Patrick D | Multimode ionization source and method for screening molecules |
| US7433787B2 (en) | 2005-08-08 | 2008-10-07 | Metabolon, Inc. | System, method, and computer program product using a database in a computing system to compile and compare metabolomic data obtained from a plurality of samples |
| US7949475B2 (en) | 2005-08-08 | 2011-05-24 | Metabolon Inc. | System and method for analyzing metabolomic data |
| EP1997049B1 (en) | 2006-03-21 | 2019-03-13 | Metabolon Inc. | A system, method, and computer program product for analyzing spectrometry data to indentify and quantify individual components in a sample |
| US20110229883A1 (en) | 2007-04-10 | 2011-09-22 | Bernd Spur | Biochemical Markers for Disease States and Genes for Identification of Biochemical Defects |
| AU2008280806B2 (en) * | 2007-07-26 | 2014-12-11 | Phenomenome Discoveries Inc. | Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders |
| WO2009032722A1 (en) * | 2007-08-29 | 2009-03-12 | The Cleveland Clinic Foundation | Carbamylated proteins and risk of cardiovascular disease |
| US7884318B2 (en) | 2008-01-16 | 2011-02-08 | Metabolon, Inc. | Systems, methods, and computer-readable medium for determining composition of chemical constituents in a complex mixture |
| WO2010045180A1 (en) * | 2008-10-13 | 2010-04-22 | Metabolon, Inc. | Biomarkers for inflammatory bowel disease and methods using the same |
| DK200970026A (en) | 2009-06-12 | 2010-12-13 | Alfa Laval Corp Ab | A centrifugal separator |
| EP2309276A1 (en) * | 2009-09-22 | 2011-04-13 | One Way Liver Genomics, S.L. | Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile |
| US8703424B2 (en) | 2010-03-22 | 2014-04-22 | Stemina Biomarker Discovery, Inc. | Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics |
| WO2011139914A1 (en) | 2010-04-29 | 2011-11-10 | Wisconsin Alumni Research Foundation | Metabolic biomarkers of autism |
| WO2011146683A1 (en) * | 2010-05-19 | 2011-11-24 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| WO2012015904A2 (en) * | 2010-07-28 | 2012-02-02 | Metabolon, Inc. | Biomarkers for prostate cancer and methods using the same |
| WO2013016700A1 (en) * | 2011-07-27 | 2013-01-31 | The Research Foundation Of State University Of New York | Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc |
| US20140303228A1 (en) * | 2011-10-18 | 2014-10-09 | Metabolon, Inc. | Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same |
| AU2012347557A1 (en) * | 2011-12-09 | 2014-07-03 | Metabolon, Inc. | Biomarkers for kidney cancer and methods using the same |
| CN114949001A (zh) * | 2012-08-29 | 2022-08-30 | 加州理工学院 | 孤独症谱系障碍的诊断和治疗 |
| IN2015DN02868A (enExample) | 2012-09-21 | 2015-09-11 | Univ Toronto | |
| DK2914748T3 (da) * | 2012-11-02 | 2019-06-11 | Stemina Biomarker Discovery Inc | Forudsigelse af udviklingen af toxicitet af farmaceutika for mennesker, under anvendelse af humane stamcellelignende celler og metaboliske forholdstal |
| JP6404834B2 (ja) * | 2013-01-31 | 2018-10-17 | メタボロン，インコーポレイテッド | インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 |
| US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US20150294081A1 (en) * | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
-
2014
- 2014-07-03 MX MX2016000293A patent/MX2016000293A/es unknown
- 2014-07-03 US US14/903,717 patent/US10060932B2/en active Active
- 2014-07-03 WO PCT/US2014/045397 patent/WO2015006160A2/en not_active Ceased
- 2014-07-03 CA CA2917483A patent/CA2917483A1/en not_active Abandoned
- 2014-07-03 EP EP14822642.6A patent/EP3019624B1/en not_active Not-in-force
- 2014-07-03 JP JP2016525390A patent/JP6763770B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-27 US US16/047,237 patent/US11268966B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Limbad et al. | Astrocyte senescence promotes glutamate toxicity in cortical neurons | |
| Paglia et al. | An unbiased metabolomic investigation of the Alzheimer’s disease brain points to a dysregulation of the mitochondrial aspartate metabolism | |
| O'Kane et al. | Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier | |
| Collins et al. | The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients | |
| JP6254561B2 (ja) | ヒト幹細胞様細胞及びメタボロミクスを使用した医薬のヒト発生毒性の予測 | |
| Cui et al. | F‑actin cytoskeleton reorganization is associated with hepatic stellate cell activation | |
| Saheb Sharif-Askari et al. | Saliva metabolomic profile of COVID-19 patients associates with disease severity | |
| Duan et al. | The potential for metabolomics in the study and treatment of major depressive disorder and related conditions | |
| JP2013525801A5 (enExample) | ||
| Grammatikos et al. | Serum sphingolipid variations associate with hepatic decompensation and survival in patients with cirrhosis | |
| BR112015017354A2 (pt) | método para detectar pelo menos uma base modificada | |
| Obeid et al. | Folate and methylation status in relation to phosphorylated tau protein (181P) and β-amyloid (1–42) in cerebrospinal fluid | |
| Storm et al. | A unifying mechanism for cancer cell death through ion channel activation by HAMLET | |
| US20190178900A1 (en) | Autism subsets | |
| Yang et al. | Altered plasma metabolic profiles in Chinese patients with multiple sclerosis | |
| JP2013525416A5 (enExample) | ||
| Smith et al. | Metabolomic biomarkers in autism: identification of complex dysregulations of cellular bioenergetics | |
| Wei et al. | A metabonomics study of epilepsy in patients using gas chromatography coupled with mass spectrometry | |
| Huang et al. | Unbiased metabolite profiling of schizophrenia fibroblasts under stressful perturbations reveals dysregulation of plasmalogens and phosphatidylcholines | |
| Al-Shalan et al. | Systemic perturbations in amino acids/amino acid derivatives and tryptophan pathway metabolites associated with murine influenza A virus infection | |
| Helms et al. | Glutamate transporters in the blood-brain barrier | |
| He et al. | Recent advances and perspectives in relation to the metabolomics-based study of diabetic retinopathy | |
| JP2016526167A5 (enExample) | ||
| Huang et al. | From genes to metabolites: HSP90B1’s role in Alzheimer’s disease and potential for therapeutic intervention | |
| Zhang et al. | Deciphering the Metabolomics‐Based Intervention of Yanghe Decoction on Hashimoto’s Thyroiditis |